Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
77 hedge funds and large institutions have $1.14B invested in Odonate Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 0 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
111% more capital invested
Capital invested by funds: $541M → $1.14B (+$599M)
35% more funds holding
Funds holding: 57 → 77 (+20)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$50.5M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$23.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.1M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$12M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.41M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$1.81M |
| 3 |
Morgan Stanley
New York
|
-$746K |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$672K |
| 5 |
JP Morgan Chase
New York
|
-$622K |
ODT Hedge Fund Activity: Q2 2019 in Review
77 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q2 2019, worth a combined $1.14B — up 111% from $541M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ODT positions and 0 closed out — a net gain of 21 holders — while 34 added to existing stakes and 15 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $50.5M. The largest seller was Sabby Management, cutting an estimated $2.41M.
- 77 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q2 2019, up from 57 in Q1 2019.
- Funds reported $1.14B of Odonate Therapeutics, Inc. Common Stock stock for Q2 2019, up 111% quarter-over-quarter.
- 21 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +21 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q2 2019 was Wellington Management Group, an estimated $50.5M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q2 2019 was Sabby Management, an estimated $2.41M sold.
Based on aggregated 13F filings for Q2 2019.